Clopidogrel has been shown to have a morbidity and mortality benefit in the prevention of ischaemic complications in patients with acute coronary syndrome and/or after percutaneous coronary intervention (PCI) 1 . 600mg of clopidogrel can not only significantly inhibit platelet inhibition acutely (within 2 hours) but also improve endothelial dysfunction in stable CAD patients via a mechanism independent of platelet function 2 . A reduction in endothelial injury after PCI also occurs in the presence of clopidogrel 3 . Clopidogrel has also been associated with improved systemic endothelial nitric oxide (NO) bioavailability in patients with coronary artery disease 2 . Endothelial nitric oxide synthase (eNOS) is the main source of NO in the vasculature 4 and its activity directly proportional to plasma nitrite concentration and reflects cardiovascular NO bioavailability 5 . 70% of resting plasma nitrite is derived from eNOS activity in humans. NO metabolites including nitrite, nitrate and RSNO are now considered a direct measure of a physiological activity of NO and also a biologically active NO reservoir. We examined the effect of acute and chronic clopidogrel on these NO metabolites, the vasodilatory effect (cGMP) and oxidative/nitrosative stress markers in the plasma in patients undergoing PCI.
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Methods:
A prospective, single centre study was undertaken with 58 patients undergoing PCI with stent implantation for stable angina enrolled after informed consent. All patients were fasted for 6 hours and maintained on aspirin (75mg/day). 36 patients studied were loaded with 600mg of clopidogrel. 22 patients already on 75mg clopidogrel maintenance dose for ≥3 days were also studied. Samples were collected pre and 2h post clopidogrel. The platelet poor plasma was isolated from each sample and snap frozen in liquid nitrogen and stored at -80°C. Plasma nitrite, nitrate and S-nitrosothiols (RSNO) were measured using ozone-based chemiluminescence (NO analyzer, NOA280i, Sievers) as it has been described previously 6 . Commercial ELISA kits were used to measure Cyclic guanosine 3', 5'-monophosphate cGMP (R&D Systems), and 3-NT (Hycult)
according to the manufacturer's instructions. Measurement of plasma total antioxidant capacity known as oxygen radical absorbance capacity assay has been described elsewhere 7 and plasma reduced thiols were measured using ThioStar Fluorescent Thiol Detection Reagent (Bioquote). 
